AstraZeneca Settles Cancer Drug Patent Lawsuits With BMS, Ono for $510 Million

AstraZeneca announced that it will pay $510 million to settle patent infringement lawsuits with Bristol Myers Squibb (BMS) and Ono Pharmaceutical involving cancer treatments using PD-1 and CTLA-4 methods.

Both BMS and Japanese drugmaker Ono Pharmaceutical had filed a series of lawsuits alleging that AstraZeneca’s marketing of Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) infringed on several of their patents.

BMS received $370 million in the settlement and Ono Pharmaceutical received $140 million.

See AstraZeneca’s Q2 report here.

To read the full story, click here to subscribe.

Related Topics